- Question from MLevine: Any new research about prophylactic Zometa for hormone-positive breast cancer? Thanks!
- Answers - Ruth Oratz, M.D., F.A.C.P. Yes. To review, there was a presentation at ASCO in June of this year which demonstrated that using Zometa (or zoledronic acid) may help prevent recurrence in young women with estrogen-receptor-positive breast cancer. Historically, Zometa has been used for the treatment of bone metastases from breast and other cancers. Zometa is not a chemotherapy drug, but rather belongs to a class of drugs called bisphosphonates. These agents, including Fosamax (chemical name: alendronate sodium), Actonel (chemical name: risedronate), clodronate (brand name: Bonefos) and others, have also been shown to help improve bone density in women who have osteopenia or osteoporosis. At the San Antonio meeting, we saw an update of a clinical trial using Zometa in postmenopausal women with estrogen-receptor-positive breast cancer who were also receiving an aromatase inhibitor as hormonal therapy. In this study, similar results were now reported for the benefit of Zometa in postmenopausal women as had previously been reported for premenopausal women. So, in addition to helping maintain bone density, Zometa may help prevent recurrences of breast cancer in hormone-receptor-positive cases.
On Wednesday, December 17, 2008, our Ask-the-Expert Online Conference was called Updates from the 2008 San Antonio Breast Cancer Symposium. Ruth Oratz, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.